Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
GUIDELINE URGES STANDARD OF CARE PRACTICED IN U.S., OTHER WEALTHY COUNTRIES, APPLY TO ALL . . . “We have no excuses,” says U.S. Global AIDS Coordinator […]
Two recently published pieces on the paucity of treatments for drug-resistant tuberculosis open with anecdotes centered on one patient each — a little girl in Mumbai, […]
A new report calls on the United Nations to include global health research and development indicators in the Sustainable Development Goals monitoring framework, set to be […]
Congress passes funding bill, avoiding government shutdown, leaving questions on potential to realize new global health goals
On Wednesday Congress approved a short-term spending bill to fund the federal government for ten weeks, hours before the midnight deadline that would have shut down […]